Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
A synthetic peptide corresponding to residues in human JNK1 was used as an immunogen.
Buffer
Store at -20 C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.
C-Jun N-terminal kinase 1 (JNK1) is a member of the mitogen-activated protein kinase (MAPK) family (1). It is activated by environmental stress and pro-inflammatory cytokines by phosphorylating a number of transcription factors, such as AP-1, and thus regulates AP-1 transcriptional activity (2). JNK1 regulates microtubule assembly in neuronal cells and microtubule-associated proteins (MAP) activity, maintaining the cytoskeletal integrity of neurons (1). In T-cells, JNK1 and its JNK2 are required for polarized differentiation of T-helper cells into Th1 cells (2). JNK1 plays a role in obesity (3). A JNK1 deficiency results in reduced adiposity and improved insulin sensitivity (3).
Related Pathway
EGFR1 Signaling Pathway
Focal Adhesion
MAPK signaling pathway
TGF Beta Signaling Pathway
Toll-like receptor signaling pathway
Wnt Signaling Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
